Recent publications of TRITON-TIMI (prasugrel) as well as PLATO (ticagrelor) have introduced new and potent antiplatelet agents, but at the same time have left clinicians with multiple choices without clear direction regarding the most appropriate use of these agents.
We present a review of the randomized controlled trial evidence examining the role of these three agents in acute coronary syndromes, and provide recommendations for the practicing physicians of their optimal use in clinical practice.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.